Enliven Therapeutics (ELVN) News Today $16.07 +0.08 (+0.50%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$16.06 -0.02 (-0.09%) As of 05/28/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Buy" by AnalystsEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has been given an average rating of "Buy" by the five ratings firms that are presently covering the stock, Marketbeat reports. Four analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation onMay 24, 2025 | marketbeat.comEnliven Therapeutics to Present at Upcoming Investor ConferencesMay 22, 2025 | prnewswire.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $81,550.00 in StockMay 22, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Northern Trust CorpNorthern Trust Corp raised its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 8.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 331,500 shares of the company's stock afMay 22, 2025 | marketbeat.comSoleus Capital Management L.P. Has $1.70 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Soleus Capital Management L.P. trimmed its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 68.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 75,405 shares of the company'sMay 21, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Outlook for ELVN EarningsEnliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Enliven Therapeutics in a research note issued to investors on Thursday, May 15th. HC Wainwright analyst R. Burns now expects that the company will earnMay 20, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Price Target Cut to $27.00 by Analysts at Jones TradingMay 19, 2025 | americanbankingnews.comPolar Capital Holdings Plc Acquires 1,739,668 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Polar Capital Holdings Plc lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 267.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,389,668 shares of the company'sMay 17, 2025 | marketbeat.comJanus Henderson Group PLC Purchases 290,153 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Janus Henderson Group PLC grew its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 27.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,331,877 shares of the company's stock after acquiring an additional 290,153 shares during the periMay 17, 2025 | marketbeat.comEnliven price target lowered to $27 from $36 at JonesResearchMay 16, 2025 | msn.comPatient Square Capital LP Increases Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Patient Square Capital LP grew its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 147.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 224,038 shares of the company's stock after buying an additional 133,466 shares during the period. EnlMay 16, 2025 | marketbeat.comNicholas Investment Partners LP Sells 16,110 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Nicholas Investment Partners LP lessened its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 9.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 157,635 shares of the company's stock after selling 16,110 shares during the period. NiMay 16, 2025 | marketbeat.comEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateMay 14, 2025 | prnewswire.comEnliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 CongressMay 14, 2025 | prnewswire.comAnish Patel Sells 6,667 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 10, 2025 | insidertrades.comEnliven Therapeutics (ELVN) to Release Quarterly Earnings on TuesdayEnliven Therapeutics (NASDAQ:ELVN) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-13-enliven-therapeutics-inc-stock/)May 8, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Joseph P. Lyssikatos Sells 5,030 SharesMay 6, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Decreased by Ally Bridge Group NY LLCAlly Bridge Group NY LLC cut its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 39.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 141,710 shares of the company's stock after sMay 4, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by 5AM Venture Management LLC5AM Venture Management LLC lowered its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 7.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,629,765 shares of the company's stock after selling 122,409 shares during tMay 4, 2025 | marketbeat.comAcuta Capital Partners LLC Decreases Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Acuta Capital Partners LLC lowered its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 9.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 267,368 shares of the company's stock after selling 29,00May 4, 2025 | marketbeat.comBoxer Capital Management LLC Acquires New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Boxer Capital Management LLC bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 671,358 shares of the company's stoMay 4, 2025 | marketbeat.comRA Capital Management L.P. Sells 212,247 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)RA Capital Management L.P. reduced its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 20.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 848,986 shares of the company's stock afteMay 3, 2025 | marketbeat.comMarshall Wace LLP Sells 96,624 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Marshall Wace LLP reduced its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 70.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,382 shares of the company's stock after selling 96,6May 3, 2025 | marketbeat.comBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 1, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Boothbay Fund Management LLCBoothbay Fund Management LLC lowered its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 21.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 104,890 shares of the company's stock after selliApril 30, 2025 | marketbeat.comLord Abbett & CO. LLC Raises Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Lord Abbett & CO. LLC lifted its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 20.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 386,211 shares of the company's stock after purchasiApril 30, 2025 | marketbeat.comArtia Global Partners LP Makes New Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Artia Global Partners LP acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 102,900 shares of the companyApril 29, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. reduced its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 18.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 650,000 shares of the compaApril 29, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading 10.8% Higher - Should You Buy?Enliven Therapeutics (NASDAQ:ELVN) Trading 10.8% Higher - Here's What HappenedApril 24, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $80,350.00 in StockApril 24, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 5,000 SharesEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 5,000 shares of the firm's stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $16.42, for a total transaction of $82,100.00. Following the completion of the sale, the chief executive officer now owns 985,392 shares in the company, valued at $16,180,136.64. This represents a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.April 23, 2025 | marketbeat.comEnliven Therapeutics: Awaiting Additional Trial DataApril 22, 2025 | seekingalpha.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Fmr LLCFmr LLC raised its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,495,871 shares of the company's stock after acquiring an additional 199,692 shApril 15, 2025 | marketbeat.comFederated Hermes Inc. Takes $2.65 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Federated Hermes Inc. acquired a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 117,552 shares of the company's stock, valuApril 15, 2025 | marketbeat.comVanguard Group Inc. Purchases 55,283 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)Vanguard Group Inc. raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,975,655 shares of the coApril 14, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week Low - Time to Sell?Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year Low - Should You Sell?April 11, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Shares Down 9.1% - Here's What HappenedEnliven Therapeutics (NASDAQ:ELVN) Shares Down 9.1% - What's Next?April 10, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 SharesApril 10, 2025 | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increase - Should You Buy?Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume - Should You Buy?April 4, 2025 | marketbeat.comEnliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual MeetingApril 2, 2025 | prnewswire.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.9% Following Insider SellingEnliven Therapeutics (NASDAQ:ELVN) Shares Down 4.9% Following Insider SellingApril 2, 2025 | marketbeat.comPictet Asset Management Holding SA Has $21.88 Million Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)Pictet Asset Management Holding SA boosted its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 16.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 972,293 shares of the company's stock afterApril 2, 2025 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $21.33, for a total value of $69,322.50. Following the sale, the chief financial officer now directly owns 23,000 shares of the company's stock, valued at $490,590. This represents a 12.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.April 1, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $22,500.00 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 1,000 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $22.50, for a total value of $22,500.00. Following the completion of the sale, the chief financial officer now directly owns 23,000 shares in the company, valued at approximately $517,500. The trade was a 4.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.March 27, 2025 | marketbeat.comBenjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMarch 27, 2025 | insidertrades.comEnliven Therapeutics (NASDAQ:ELVN) Trading Down 7.8% - Here's What HappenedEnliven Therapeutics (NASDAQ:ELVN) Trading Down 7.8% - Should You Sell?March 26, 2025 | marketbeat.com16,322 Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Purchased by Intech Investment Management LLCIntech Investment Management LLC purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,322 shares of the company's stock, valued at approximaMarch 26, 2025 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,500 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 12,500 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $20.61, for a total value of $257,625.00. Following the sale, the insider now directly owns 1,002,688 shares of the company's stock, valued at approximately $20,665,399.68. This represents a 1.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.March 22, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock PriceHC Wainwright upped their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research note on Friday.March 22, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $257,625.00 in StockMarch 22, 2025 | insidertrades.com Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address ELVN Media Mentions By Week ELVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELVN News Sentiment▼0.420.87▲Average Medical News Sentiment ELVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELVN Articles This Week▼53▲ELVN Articles Average Week Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcellx News Today Metsera News Today Viking Therapeutics News Today Akero Therapeutics News Today Alvotech News Today Catalyst Pharmaceuticals News Today Crinetics Pharmaceuticals News Today Scholar Rock News Today Merus News Today MorphoSys News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELVN) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELVN Stock Free ELVN Stock Alerts